Clinical Trial Update: Long-term Persistence Study to Assess a Booster Dose of GSK Biologicals' Hib-MenC [Phase 3]

View source ↗

Summary

This Phase 3 long-term persistence study evaluated a booster dose of GSK's Hib-MenC conjugate vaccine. The trial results were completed and posted in 2011.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Haemophilus Influenzae Type Infection
• Meningococcal Disease

Drugs mentioned

• Hib-MenC conjugate vaccine (Haemophilus influenzae type b and Neisseria meningitidis serogroup C conjugate vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Haemophilus Influenzae Type b, Neisseria Meningitidis | Phase 3 | Status: COMPLETED | Results posted: 2011-01-14